Not Yet RecruitingPhase 4

JAK Inhibitor Dose TAPering Strategy Study

308 participantsStarted 2025-01-01

Plain-language summary

This study aims to assess the feasibility of tapering JAK inhibitors in rheumatoid arthritis patients in low disease activity by comparing a group of patients tapering the JAK inhibitor dosage to a group of patients continuing the full-dose. Participants will: * Either take 1. JAK inhibitor dose-tapering strategy. 2. JAK inhibitor continuous therapy strategy. * Visit the clinic once every 3 months for checkups and tests * Keep a diary of their treatment intake and symptoms

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Aged ≥ 18 years at baseline.
✓. Rheumatoid arthritis defined by the ACR/EULAR criteria.
✓. Treated with a JAK inhibitor, full dose for at least 6 months.
✓. The JAK inhibitor is prescribed as monotherapy or combined with a csDMARD with a stable dosage for at least 3 months before inclusion.
✓. Being in LDA (CDAI≤10) for at least 6 months.
✓. With a CRP level below the laboratory standard within the month before the inclusion visit.
✓. Women of childbearing potential (WCBP) must have a negative pregnancy test before starting study
✓. Concomitant disease needing to be treated by the JAK inhibitor at full-dose (for example inflammatory bowel disease).

What they're measuring

proportion of patients still receiving a JAK-inhibitor

Timeframe: 12 post baseline

Trial details

NCT IDNCT06687551

SponsorUniversity Hospital, Toulouse

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2029-04-01

Contact for this trial

Adeline RUYSSEN-WITRAND, MD

05 61 77 56 26 ruyssen-witrand.a@chu-toulouse.fr

View on ClinicalTrials.gov More Rhumatoid Arthisis trials